No Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin 2 Receptor Blocker Intake with Acute Kidney Injury in Patients Undergoing Kidney Biopsy

Authors:
  • SPSlobodan Peric
    Slobodan Peric
  • SMSalome Masghati
    Salome Masghati
  • MWMichael Wolzt
    Michael Wolzt
  • WHWalter H. Hörl
    Walter H. Hörl
  • ASAfschin Soleiman
    Afschin Soleiman
  • VFValentin Fuhrmann
    Valentin Fuhrmann
Open Access
Publisher website
Google Scholar
Abstract
Background: Treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 2 receptor blockers (ARBs) is associated with an increased risk for acute kidney injury after cardiovascular interventions. However, for patients undergoing kidney biopsy, no data is available. Methods: Four hundred and sixty-six patients undergoing kidney biopsy were retrospectively analyzed of whether or not concomitant intake of ACEIs or ARBs impairs kidney function. Results: Three hundred and twenty-three patients received ACEIs or ARBs or both before kidney biopsy. ACEI/ARB intake had no effect on kidney function compared to patients without this medication (all p > 0.05). Conclusion: Treatment with ACEIs or ARBs is not associated with risk of acute kidney injury in subjects undergoing kidney biopsy.